Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Nasdaq Hearings Panel Granted Alzamend's Request To Continue Its Listing, Subject To Alzamend Demonstrating Compliance, On Or Before September 23, 2024
Alzamend Neuro, Inc. (NASDAQ:ALZN) ("Alzamend"), a clinical-stage biopharmaceutical company focused on developing novel products for the treatment of Alzheimer's disease ("Alzheimer's"), bipolar disorder ("BD"), major depressive disorder ("MDD") and post-traumatic stress disorder ("PTSD"), announced today that the Nasdaq Hearings Panel ("Panel") granted Alzamend's request to continue its listing on The Nasdaq Capital Market ("Nasdaq"), subject to Alzamend demonstrating compliance, on or before September 23, 2024, with Listing Rule 5550(b)(1), which requires stockholder equity of at least $2.5 million (the "Stockholder Equity Rule"), and satisfying all applicable requirements for continued listing on Nasdaq.
Alzamend Neuro, Inc.（纳斯达克股票代码：ALZN）（“Alzamend”）是一家临床阶段的生物制药公司，专注于开发用于治疗阿尔茨海默氏病（“阿尔茨海默氏症”）、躁郁症（“BD”）、重性抑郁症（“MDD”）和创伤后应激障碍（“创伤后应激障碍”）的新产品，今天宣布，纳斯达克听证小组（“小组”）（“小组”）”）批准了Alzamend继续在纳斯达克资本市场（“纳斯达克”）上市的请求，前提是Alzamend在2024年9月23日当天或之前证明遵守了《上市规则》5550 (b) (1)，该规则要求股东权益至少为250万美元（“股东权益规则”），并满足继续在纳斯达克上市的所有适用要求。
译文内容由第三方软件翻译。